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PTCH1, BCOR, CLIC6, TLL2, COL1A1, PTPRK). Notably, mutations in 
BCOR and PTCH1 have been previously implicated in both systemic neuro-
endocrine tumors as well as primary tumors of the pituitary gland, while 
MYO18A, FGF4, and PTPRK mutations had not been reported in systemic 
neuroendocrine tumors but have been implicated in tumor migration and 
pituitary adenoma progression. In summary, these data demonstrated an ex-
pected mutational pattern indicating a systemic lung neuroendocrine origin 
but also revealed new mutations previously implicated in primary pituitary 
pathologies that may have evolutionarily drove divergence from the primary 
tumor. Further genome studies of these rare lesions may yield further insight 
into the genetic alterations underlying metastasis to the sellar region.
29. ROLE OF AGE AND CNS MYELOID CELLS ON BREAST CANCER 
BRAIN METASTASIS
Alex Man Lai Wu1, Selamawit Gossa2, Ramakrishna Samala3, 
Monika Chung1, Brunilde Gril1, Howard Yang1, Helen Thorsheim4, 
Andy Tran1, Debbie Wei1, Kristine Isanogle5, Yuan Yang1, Emma Dolan1, 
Christina Robinson5, Simone Difilippantonio5, Maxwell Lee1, 
Quentin Smith4, Dorian McGavern2, Lalage Wakefield1, and Patricia Steeg1; 
1National Cancer Institute, Bethesda/MD, USA, 2National Institute of 
Neurological Disorders and Stroke, Bethesda, MD, USA, 3South University, 
Columbia, SC, USA, 4Texas Tech University Health Sciences Center, 
Amarillo, TX, USA, 5National Cancer Institute, Frederick, MD, USA
Women diagnosed with breast cancer at a younger age (typically defined 
as < 40 years old) often have a poorer prognosis and an increased risk of 
brain metastasis compared to their older counterparts. Multivariate ana-
lyses accounting for differences in tumor characteristics have shown that age 
is an independent predictor of worse outcome. We therefore hypothesized 
that rather than intrinsic tumor properties, extrinsic microenvironmental 
factors contribute to age-related differences in aggressiveness. The effect of 
age was examined by injecting brain-selected breast cancer cells into young 
(2 – 6 months) and older (>12 months) mice. In four brain metastasis models 
examined, young mice developed 2- to 16-fold (p < 0.05) more brain metas-
tases compared to older mice. The effect of age was not observed in mouse 
breast cancer models that metastasize to liver and lungs, suggesting that this 
is an organ-specific phenomenon. Flow cytometry-based immune-profiling 
of mouse brains showed that T-cells (CD4+, CD8+, and FOXP3+CD25+ 
regulatory T-cells), monocytes and neutrophils were elevated in brains with 
metastases, but the abundance of these populations did not vary dramatic-
ally with age. Furthermore, antibody-based depletion of T-cells, monocytes 
and neutrophils did not significantly alter brain metastasis development. 
Microglia, which are resident CNS myeloid cells, were 1.5-fold more abun-
dant in young brains compared to older brains. Depletion of CNS myeloid 
cells using the colony stimulating factor-1-receptor inhibitor PLX3397 re-
duced brain metastatic tumor burden in young mice by 2.1-fold (p < 0.001). 
Importantly, loss of CNS myeloid cells/microglia, which are normally more 
activated in aged mice and thus may protect the older brain against me-
tastasis, did not augment brain metastasis formation in older mice. These 
results suggest that the younger brain is more permissive for breast cancer 
metastasis and that targeting resident CNS myeloid cells may be an effective 
strategy to prevent brain metastasis development in younger patients.
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BACKGROUND: Tumor Treating Fields (TTFields) are non-invasive, 
loco-regional, anti-mitotic treatment modality comprising alternating elec-
tric fields. TTFields have demonstrated efficacy in preclinical non-small cell 
lung cancer (NSCLC) models. TTFields treatment to the brain was safe and 
extended overall survival in newly-diagnosed glioblastoma. The objective of 
the METIS study [NCT02831959] is evaluation of the efficacy and safety of 
TTFields in NSCLC patients with brain metastases. METHODS: NSCLC 
patients (N=270) with 1–10 brain metastases were randomized 1:1 to stereo-
tactic radio surgery (SRS) followed by continuous TTFields ((150 kHz, > 18 
hours/day) within 7  days of SRS or supportive care. The portable device 
delivered TTFields to the brain using 4 transducer arrays, while patients 
received the best standard-of-care for systemic disease. Patients were fol-
lowed every two months until second intracranial progression. Key inclu-
sion criteria: KPS ≥70, new diagnosis of 1 inoperable or 2–10 supra- and/or 
infratentorial brain metastases from NSCLC amenable to SRS; and optimal 
therapy for extracranial disease. Prior WBRT, surgical resection of metas-
tases, or recurrent brain metastases were exclusionary. Primary endpoint 
was time to 1st intracranial progression. Secondary endpoints included 
time to neurocognitive failure (HVLT, COWAT and TMT), overall survival, 
radiological response rate (RANO-BM and RECIST V1.1); quality-of-life; 
adverse events; time to first/second intracranial progression for patients with 
1–4 and 5–10 brain metastases; bi-monthly intracranial progression rate 
from 2–12 months; and time to second intracranial and distant progression. 
The sample size (N=270) was calculated using a log-rank test (Lakatos 1988 
and 2002) with 80% power at two sided alpha of 0.05 to detect a hazard 
ratio of 0.57. On September, 2019, an independent Data Monitoring Com-
mittee (DMC) reviewed METIS trial data collected to that point. The DMC 
concluded that no unexpected safety issues had emerged and recommended 
continuation of the METIS study as planned.
31. RADIATION NECROSIS IN STEREOTACTIC RADIOSURGERY 
AND CHECKPOINTS INHIBITORS FOR BRAIN METASTASES FROM 
LUNG ADENOCARCINOMA
James Jurica1,2, Shraddha Dalwadi1,2, David Baskin2, Eric Bernicker2, 
Brian Butler2, Robert Rostomily2, Bin Teh2, Ivo Tremont-Lukats2, and 
Andrew Farach2; 1Baylor College of Medicine, Houston, TX, USA, 
2Houston Methodist Hospital, Houston, TX, USA
PURPOSE: Treatment with stereotactic radiosurgery (SRS) and immune 
checkpoint inhibitors (ICI) is increasingly common for brain metastases 
(BM) from lung adenocarcinoma. Rates of radiation necrosis (RN) with SRS 
in the setting of ICIs is an ongoing area of research. We investigated rates 
of RN in patients with BM from lung adenocarcinoma treated with SRS 
with or without concurrent ICIs. METHODS: We identified 39 patients at 
a single institution who underwent SRS treatment for BM from lung adeno-
carcinoma. Of these, 19 (49%) received SRS without ICIs and 20 (51%) 
patients received ICIs within a month of SRS. The rate of RN, defined by 
MRI features and histology when available, was compared between each 
group using multivariate analysis. Kaplan Meier survival estimates were 
calculated based on overall survival and compared to median survival pre-
dicted by the graded prognostic assessment. RESULTS: Overall survival 
for all patients from diagnosis of brain metastases was 16.6 months (range 
3.6–45.9) and median survival predicted by the graded prognostic assess-
ment was 13.7 months (range 6.9–26.5). In total 11 (28%) patients devel-
oped MRI and/or histologic evidence for RN during the follow-up period; 5 
of 20 (25%) from the SRS with ICI group and 6 of 19 (31%) from the SRS 
without ICI group. In multivariate analysis, ICI treatment had no signifi-
cant impact on rates of RN between groups (OR 0.72 [95% CI: 0.17–2.93]; 
p=0.65) while bevacizumab treatment was associated with a decreased RN 
risk (OR 0.88 [95% CI: 0.43–0.99]; p=0.02). CONCLUSION: Retro-
spective analysis of patients with BM from lung adenocarcinoma treated 
with SRS suggested that administration of ICIs does not increase risk for 
development of RN. Further, concomitant treatment with bevacizumab may 
decrease risk of RN. These findings suggest that patients with BM from lung 
adenocarcinoma can be treated with combination therapy without increased 
risk of neurologic toxicity.
32. TREATMENT MONITORING OF IMMUNOTHERAPY AND 
TARGETED THERAPY USING AMINO ACID PET IN PATIENTS 
WITH BRAIN METASTASES
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PURPOSE: Recently, the RANO group has analyzed the additional diag-
nostic value of amino acid PET in patients with primary and secondary 
brain tumors and recommended the use of this imaging technique in add-
ition to conventional MRI. Here, we investigated the value of PET using 
the radiolabled amino acid O-(2-[18F]fluoroethyl)-L-tyrosine (FET) for 
treatment monitoring of immune checkpoint inhibition (ICI) or targeted 
therapy (TT) alone or in combination with radiotherapy in patients with 
brain metastases (BM) since contrast-enhanced MRI often remains incon-
clusive. METHODS: We retrospectively identified 40 patients with 107 BM 
secondary to melanoma (n=29 with 75 BM) or non-small cell lung cancer 
(n=11 with 32 BM) treated with ICI or TT who had FET PET (n=60 scans) 
for treatment monitoring from 2015–2019. The majority of patients (n=37; 
92.5%) had radiotherapy during the course of disease. In 27 patients, FET 
PET was used for the differentiation of treatment-related changes from BM 
relapse following ICI or TT. In 13 patients, FET PET was performed for re-
sponse assessment to ICI or TT using baseline and follow-up scans (median 
time between scans, 4.2 months). In all lesions, static and dynamic FET PET 
